Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02379793
Other study ID # LP0076-1080
Secondary ID
Status Completed
Phase Phase 1
First received February 26, 2015
Last updated June 13, 2016
Start date March 2015
Est. completion date April 2015

Study information

Verified date February 2015
Source LEO Pharma
Contact n/a
Is FDA regulated No
Health authority Japan: Pharmaceuticals and Medical Devices Agency
Study type Interventional

Clinical Trial Summary

The purpose of the study is to investigate skin irritation of LEO 80185 gel, gel vehicle and Liquid Paraffin in healthy Japanese male subjects.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date April 2015
Est. primary completion date April 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria:

1. Signed informed consent has been obtained.

2. Healthy Japanese male subjects.

3. Aged 20 to 40 years inclusive.

4. Subjects without signs of skin irritation/disease/disorders/symptoms or blemishes on test sites (e.g. erythema, dryness, roughness, scaling, scars, moles, sunburn).

5. Subjects without a significant abnormality, as judged by the (sub)investigator

Exclusion Criteria:

1. Body Mass Index outside the range 18-25 kg/m²

2. History of alcohol or drug abuse.

3. History of allergic reaction to any medications.

4. Any disease that could in any way confound assessment of the test sites.

5. Known or suspected hypersensitivity to any component of LEO 80185 gel.

6. Known or suspected hepatic, renal or cardiac disorders.

7. Known or suspected disorders of calcium metabolism associated with hypercalcaemia or albumin-corrected serum calcium above the reference range from the sample taken during screening.

8. Subjects suspected of infection based on the infection testing results from the sample taken during screening (Hepatitis B surface antigen, HCV antibody, HIV antigen/antibody, serological test for syphilis).

9. Use of systemic, locally injected or inhaled corticosteroids within 4 weeks of Day 1.

10. Use of vitamin D or calcium supplements, or systemic vitamin D analogues within 4 weeks of Day 1.

11. Use of any medication (systemic or topical) within 2 weeks of Day 1.

12. Subjects who have received treatment with any non-marketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within 4 weeks or 5 half-lives of Day 1, whichever is longest.

13. Current participation in any other interventional clinical trial.

14. Previously enrolled in this clinical trial.

15. Previous or current photo-induced or photo-aggravated disease (e.g. abnormal response to sunlight).

16. Exposure to excessive or chronic ultraviolet radiation (e.g. sunlight, sun lamps, tanning booths or photo-therapy) within 4 weeks of Day 1.

17. Subjects (or their partner) not using an adequate method of contraception during the trial (Day 1-4).

18. In the opinion of the (sub)investigator, participation in the trial is inappropriate.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
LEO 80185 gel, vehicle, liquid paraffin
Each subject has all 3 treatments applied at the same time. Each treatment is applied once to 2 locations on the subject.

Locations

Country Name City State
Japan Medical Co. LTA HAKATA Clinic Random Square 5F, 6-18 Tenyamachi, Hakata-ku Fukuoka

Sponsors (1)

Lead Sponsor Collaborator
LEO Pharma

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Skin irritation measured as -, +/-, +, ++, +++, ++++ 4 days Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04971200 - Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo Early Phase 1
Active, not recruiting NCT05525741 - Assessment of Circulating Fubctional Mitochondrias in Vitiligo Patients N/A
Completed NCT01093911 - Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) Phase 1
Completed NCT00147511 - Time To Efficacy and Onset Of Action Of Linezolid Phase 4
Completed NCT02355639 - A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin Phase 1
Completed NCT01764594 - Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus Phase 1
Active, not recruiting NCT05185258 - Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study Phase 4
Completed NCT02985437 - Safety and Tolerability of Topically Applied Bovine Lung Surfactant on Intact Skin Phase 1
Not yet recruiting NCT06427889 - Treatment Effects of Two Pharmaceutical Skin Care Creams for Xerotic Feet Among Persons With Diabetes Phase 4
Completed NCT02518048 - A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris Phase 2
Withdrawn NCT03196115 - Biomarker for Hyaline Fibromatosis Syndrome (BioHFS)
Completed NCT02416258 - A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123) Phase 2

External Links